Further analysis identified prominent differences in overall survival among these three groups, with the best outcome for patients in the TET2high/YBX1low/ASLlow or ASS1low group and the worst outcome for those in the TET2low/YBX1high/ASLhigh or ASS1high group (Fig. 5h, i), demonstrating TET2-YBX1-urea cycle axis is not only vital for the suppression of mTORC1 signaling, but also represents clinical relevance for prognosis of liver cancer. The gene discussed is TET2; the disease is liver cancer.